glp 1 agonist vs sglt2 inhibitor Disparities in or Glucagon-Like Peptide Receptor Initiation Among Medicare-Insured Adults With CKD in the United States Kidney and Cardiovascular Effectiveness of

doi: 10.15620/cdc:106273

[11c]-PK11195 PET: Quantification of Neuroinflammation and a Monitor of Anti-Inflammatory Treatment in Parkinsons Disease

Dietary composition significantly influences GLP-1 secretion, with specific macronutrients and food components demonstrating particular efficacy

10.1210/en.2014-1978 74 PerkovicV.TuttleK

Nearly 25% of the population in western countries have NAFLD and up to 6.5% fulfill the criteria of NASH ( NAFLD is considered the hepatic manifestation of metabolic syndrome ( No pharmacological therapies are approved for the treatment of NAFLD and lifestyle changes focusing on caloric restriction and weight loss constitute the general treatment recommendations